According to GuruFocus Insider Data, these were the largest CEO buys during the past week.
Relay Therapeutics
Relay Therapeutics Inc. (RLAY, Financial) President and CEO Sanjiv Patel bought 25,000 shares on July 20 at a price of $20.00. The price of the stock has increased by 66% since then.
Relay Therapeutics operates as a clinical-stage precision medicines company. It engages in transforming the drug discovery process with an initial focus on enhancing small molecule therapeutic discovery in targeted oncology. Its product candidates include RLY-1971, an oral small molecule inhibitor that is in Phase 1 dose escalation studies in patients with advanced or metastatic solid tumors; RLY-4008, an oral small molecule selective inhibitor for patients with advanced solid tumors having oncogenic FGFR2 alterations; and RLY-PI3K1047, a lead compound that targets cancer-associated mutant variants of phosphoinositide 3-kinase alpha.
The company has a market cap of $2.88 billion. Its shares traded at $33.20 as of July 24.
On July 15, 2020, the company announced the pricing of its initial public offering of 20,000,000 shares of its common stock at a price to the public of $20.00 per share. The offering is expected to close on July 20, subject to the satisfaction of customary closing conditions.
Director Mark Murcko bought 25,000 shares on July 20 at a price of $20. Since then, the price of the stock has increased by 66%.
Director Jami Rubin bought 25,000 shares on July 20 at a price of $20. The price of the stock has increased by 66% since then.
Director Douglas S. Ingram bought 25,000 shares on July 20 at a price of $20. Since then, the price of the stock has increased by 66%.
General Counsel Brian Adams bought 10,000 shares on July 20 at a price of $20. The price of the stock has increased by 66% since then.
Pandion Therapeutics
Pandion Therapeutics Inc. (PAND, Financial) CEO Rahul Kakkar bought 14,000 shares on July 21 at a price of $18.00. Since then, the price of the stock has decreased by 0.83%.
Pandion Therapeutics is a clinical stage biopharmaceutical company that focuses on developing various therapeutics to address the unmet needs of patients suffering from autoimmune diseases. Its lead product candidate is PT101, which is in Phase 1a clinical trials for the treatment of various autoimmune and inflammatory diseases. The company has a collaboration with Astellas Pharma Inc. to develop locally acting immunomodulators for autoimmune diseases of the pancreas.
The company has a market cap of $509.19 million. Its shares traded at $17.85 as of July 24.
On July 16, Pandion Therapeutics announced the pricing of its initial public offering of 7,500,000 shares of its common stock at a public offering price of $18.00 per share. The offering is expected to close on July 21, subject to customary closing conditions.
10% Owner Roche Holding Ltd. bought 36,111 shares on July 21 at a price of $18. The price of the stock has decreased by 0.83% since then.
Director and 10% Owner Mitchell Mutz bought 46,111 shares on July 21 at a price of $18. Since then, the price of the stock has decreased by 0.83%.
10% Owner Polaris Entrepreneurs' Fund Vi bought 36,111 shares on July 21 at a price of $18. The price of the stock has decreased by 0.83% since then.
10% Owner Boxer Capital, LLC bought 722,222 shares on July 21 at a price of $18. Since then, the price of the stock has decreased by 0.83%.
Director and 10% Owner Jill Carroll bought 361,111 shares on July 21 at a price of $18. The price of the stock has decreased by 0.83% since then.
For the complete list of stocks bought by their company CEOs, go to: CEO Buys.
Disclosure: I do not own stock in any of the companies mentioned in the article.
Not a Premium Member of GuruFocus? Sign up for a free 7-day trial here.
